Biased agonism of the angiotensin II type I receptor a potential strategy for the treatment of acute heart failure

International Heart Journal

Volumn 56, Issue 5, 2015, Pages 485-488

  Ikeda, Yuichi ^a   Kumagai, Hidetoshi ^a   Motozawa, Yoshihiro ^a   Suzuki, Jun Ichi ^a   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

GPCR; Novel cardiovascular therapeutic; TRV027; arrestin; arrestin biased ligand

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; BETA ARRESTIN; CARDIOVASCULAR AGENT; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL TRISPHOSPHATE; SII; TRV 027; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; OLIGOPEPTIDE; RETINA S ANTIGEN; SARCOSINE-ARGINYL-VALYL-TYROSYL-ISOLEUCYL-HISTIDYL-PROLYL-ALANINE;

ACUTE HEART FAILURE; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EC50; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; MECHANICAL STRESS; PARTIAL AGONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; DRUG EFFECTS; HEART FAILURE; HEART MUSCLE CELL; METABOLISM; PATHOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARRESTINS; CLINICAL TRIALS, PHASE II AS TOPIC; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; OLIGOPEPTIDES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84942881979     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.15-256     Document Type: Article

References (24)

1. Vassilatis DK, Hohmann JG, Zeng H, et al. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 2003; 100: 4903-8.
2. Kamo T, Akazawa H, Komuro I. Pleiotropic effects of angiotensin II receptor signaling in cardiovascular homeostasis and aging. Int Heart J 2015; 56: 249-54.
3. Chang RS, Siegl PK, Clineschmidt BV, et al. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. J Pharmacol Exp Ther 1992; 262: 133-8.
4. Siegl PK, Chang RS, Mantlo NB, et al. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther 1992; 262: 139-44.
5. Ishimitsu T, Honda T, Ohno E, et al. Year-long antihypertensive therapy with candesartan completely prevents development of cardiovascular organ injuries in spontaneously hypertensive rats. Int Heart J 2010; 51: 359-64.
6. Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biocheml J 2003; 375: 503-15. (Review)
7. Audet M, Bouvier M. Restructuring G-protein- coupled receptor activation. Cell 2012; 151: 14-23. (Review)
8. Violin JD, Crombie AL, Soergel DG, Lark MW. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 2014; 35: 308-16. (Review)
9. Wei H, Ahn S, Shenoy SK, et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A 2003; 100: 10782-7.
10. Holloway AC, Qian H, Pipolo L, et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 2002; 61: 768-77.
11. Hunton DL, Barnes WG, Kim J, et al. Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol 2005; 67: 1229-36.
12. DeWire SM, Kim J, Whalen EJ, Ahn S, Chen M, Lefkowitz RJ. Beta-arrestin-mediated signaling regulates protein synthesis. J Biol Chem 2008; 283: 10611-20.
13. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ. {beta}-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation. J Biol Chem 2009; 284: 8855-65.
14. Rajagopal K, Whalen EJ, Violin JD, et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A 2006; 103: 16284-9.
15. Aplin M, Christensen GL, Schneider M, et al. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin Pharmacol Toxicol 2007; 100: 289-95.
16. Zou Y, Akazawa H, Qin Y, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-506.
17. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal 2010; 3: ra46.
18. Billet S, Bardin S, Verp S, et al. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest 2007; 117: 1914-25.
19. Zhai P, Yamamoto M, Galeotti J, et al. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005; 115: 3045-56.
20. Violin JD, DeWire SM, Yamashita D, et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010; 335: 572-9.
21. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC Jr. Cardiorenal actions of TRV120027, a novel β-arrestinbiased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 2011; 4: 770-8.
22. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC Jr. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail 2012; 5: 627-34.
23. Soergel DG, Subach RA, Cowan CL, Violin JD, Lark MW. First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol 2013; 53: 892-9.
24. Felker GM, Butler J, Collins SP, et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail 2015; 3: 193-201. (Review)